VANDA PHARMACEUTICALS INC. Accrued Investment Income Receivable
VANDA PHARMACEUTICALS INC. (VNDA) had Accrued Investment Income Receivable of $99.00 thousand as of 2014-03-31, per its 10-Q filed 2014-05-08.
Discontinued › Balance Sheet › Assets
us-gaap:AccruedInvestmentIncomeReceivable · last filed 2014-05-08
- 2014-03-31: Accrued Investment Income Receivable $99.00K.
- 2013-12-31: Accrued Investment Income Receivable $128.00K.
- 2013-09-30: Accrued Investment Income Receivable $10.00K.
- 2013-06-30: Accrued Investment Income Receivable $60.00K.
| Period end | Accrued Investment Income Receivable |
|---|---|
| 2014-03-31 | $99.00K 10-Q · filed 2014-05-08 |
| 2013-12-31 | $128.00K 10-Q · filed 2014-05-08 |
| 2013-09-30 | $10.00K 10-Q · filed 2013-11-08 |
| 2013-06-30 | $60.00K 10-Q · filed 2013-07-31 |
| 2013-03-31 | $223.00K 10-Q · filed 2013-05-10 |
| 2012-12-31 | $276.00K 10-K · filed 2014-02-25 |
| 2012-09-30 | $252.00K 10-Q · filed 2012-11-08 |
| 2012-06-30 | $381.00K 10-Q · filed 2012-08-03 |
| 2011-12-31 | $244.00K 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |